ALK and non-small cell lung carcinoma: Due the multi-target nature of ALK inhibitors, crizotinib and next generation ALK TKIs are being utilized in the treatment of ROS1+ NSCLC, with observations being made that the CNS is frequently a site of progression in as many as 50% of ROS1+ NSCLC (93).